{"nctId":"NCT02585895","briefTitle":"Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment","startDateStruct":{"date":"2015-12-21","type":"ACTUAL"},"conditions":["Hypercholesterolemia"],"count":39,"armGroups":[{"label":"Evolocumab","type":"EXPERIMENTAL","interventionNames":["Biological: Evolocumab"]},{"label":"Low Density Lipoprotein Cholesterol (LDL-C) Apheresis","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Evolocumab","Procedure: Low-density Lipoprotein Cholesterol (LDL-C) Apheresis"]}],"interventions":[{"name":"Evolocumab","otherNames":["Repatha","AMG 145"]},{"name":"Low-density Lipoprotein Cholesterol (LDL-C) Apheresis","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female, ≥ 18 years of age\n* Subject has been receiving regular apheresis for LDL-C lowering for at least 3 months immediately prior to lipid screening and has a treatment goal of LDL-C \\< 100 mg/dL (2.6 mmol/L), and has been receiving LDL-C apheresis during the last ≥ 4 weeks prior to lipid screening at regular QW or Q2W schedule and with no changes in apheresis type\n* Subject is receiving lipid-lowering pharmacological background therapy which includes a high-intensity statin dose (moderate-intensity statin dose with attestation that a higher dose is not appropriate for the subject) unless the subject has a history of statin intolerance\n* Lipid-lowering therapy status (ie, any therapy for lowering lipids, including apheresis type and frequency) must be unchanged for ≥ 4 weeks prior to LDL-C screening\n* Pre-apheresis LDL-C is ≥ 100 mg/dL (≥ 2.6 mmol/L) and ≤ 190 mg/dL (≤ 4.9 mmol/L) at screening\n* Fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L) at screening.\n\nExclusion criteria:\n\n* Known homozygous familial hypercholesterolemia\n* Missing any apheresis session is medically contraindicated or inappropriate\n* Stopping apheresis would be inappropriate in the opinion of the investigator even if LDL-C is controlled to \\< 100 mg/dL with other therapies\n* Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or stroke within 3 months prior to randomization.\n* Uncontrolled hypertension","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Apheresis Avoidance at the End of Randomized Therapy","description":"Avoidance of apheresis at end of randomized therapy was defined as no apheresis at week 5 and week 6. Aperesis at weeks 5 or 6 was based on LDL-C level at week 4:\n\nparticipants with LDL-C ≥ 100 mg/dL at week 4 received apheresis at week 5 (participants who received apheresis QW before study entry) or week 6 (participants who received apheresis Q2W prior to study entry). If LDL-C was \\< 100 mg/dL at week 4, no apheresis was performed at week 5 or week 6, irrespective of assigned treatment group.\n\nParticipants who ended the study prior to week 6 were considered as not achieving apheresis avoidance.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.0","spread":null},{"groupId":"OG001","value":"84.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Low-density Lipoprotein Cholesterol","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.61","spread":"3.97"},{"groupId":"OG001","value":"-50.13","spread":"4.03"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-high-density Lipoprotein-Cholesterol","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.80","spread":"3.29"},{"groupId":"OG001","value":"-44.58","spread":"3.34"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total Cholesterol/High-density Lipoprotein Cholesterol Ratio","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.15","spread":"2.65"},{"groupId":"OG001","value":"-35.65","spread":"2.67"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":4},"commonTop":["Headache","Myalgia","Diarrhoea","Fatigue","Rash"]}}}